Canaccord Genuity Reiterates a 'Buy' on Cytokinetics (CYTK); Keep Moving Forward
Tweet Send to a Friend
Canaccord Genuity reiterates a 'Buy' on Cytokinetics (NASDAQ: CYTK) price target of $6.00.
Analyst, Ritu Baral, said, "Reiterate rating ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Analyst, Ritu Baral, said, "Reiterate rating ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
